Home > Anti A3 Adenosine Receptor
Search results for: Anti A3 Adenosine Receptor
#34831054 2021/10/21 To Up
Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy.Extracellular adenosine accumulates in the environment of numerous tumors. For years, this fact has fueled preclinical research to determine whether adenosine receptors (ARs) could be the target to fight cancer. The four ARs discovered so far, A, A, A and A, belong to the class A family of G protein-coupled receptors (GPCRs) and all four have been involved in one way or another in regulating tumor progression. Prompted by the successful anti-cancer immunotherapy, the focus was placed on the ARs more involved in regulation of immune cell differentiation and activation and that are able to establish molecular and functional interactions. This review focuses on the potential of A and A receptor antagonists in cancer control and in boosting anti-cancer chemotherapy and immunotherapy. The article also overviews the ongoing clinical trials in which AR and AR ligands are being tested in anti-cancer therapy.
Rafael Franco, Rafael Rivas-Santisteban, Gemma Navarro, Irene Reyes-Resina
1280 related Products with: Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy.0.1 mg1000 100.00 ug100ul100 1 ml100 μg100ul100 100.00 ul
#34826631 2021/11/23 To Up
CF101 alleviates OA progression and inhibits the inflammatory process via the AMP/ATP/AMPK/mTOR axis.CF101 (IB-MECA) is an adenosine A3 receptor agonist that has anti-inflammatory and pain-relieving properties. Adenosine A3 receptor activation can delay the process of Osteoarthritis(OA) and prevent the occurrence of OA. However, the mechanism of CF101 on OA is still unknown. This study aimed to investigate the effect of CF101 on rats induced by anterior cruciate ligament-transection (ACLT) and rat chondrocytes induced by IL-1Ã. ACLT-induced OA rats were administered CF101, and autophagy levels were measured to determine whether CD101 had an autophagy-mediated protective effect on articular cartilage. Furthermore, the mechanism by which CF101 protected articular cartilage in IL-1Ã-induced chondrocytes mimicking OA was investigated. In rats treated with ACLT, CF101 was able to delay the progression of OA, as well as reduce inflammation and type II collagen degradation factors. In addition, in vitro experiments revealed that CF101 reduced type II collagen degradation factors in OA chondrocytes. In rats treated with ACLT and OA chondrocytes, CF101 enhanced autophagy and increased the ratio of AMP/ATP and AMPK protein levels while decreasing mTOR expression. Treatment of OA chondrocytes with 3-MA prior to treatment with CF101 resulted in inhibition of autophagy factor levels, as well as increased levels of inflammatory factors and type II collagen degradation compared to the CF101 group. These findings demonstrated that CF101 could protect articular cartilage against OA by enhancing the ratio of ATP/AMP and altering the AMPK/mTOR pathway to enhance autophagy and reduce inflammation. In addition, inhibition of autophagy resulted in a reduced CF101 effect.
Liu Lin, Hui Bai, Guangming Jiao, XinYu Wang, Zhiheng Zhang, Xiaopeng Song, Tianwen Ma, TingLi, Li Gao
1991 related Products with: CF101 alleviates OA progression and inhibits the inflammatory process via the AMP/ATP/AMPK/mTOR axis.1250 IU 100 G100.00 ul1500 Units 100ul100 U
#34697594 2021/10/21 To Up
Adenosine: a partially discovered medicinal agent.A plethora of chemicals exists in human body which can alter physiology in one way or other. Scientists have always been astounded by such abilities of chemicals but as the technology advances, even the chemical which was once expected to be well known changes its status to not really well known. Adenosine is one of the chemicals which is in consonance with the aforementioned statements, although previous articles have covered vast information on role of adenosine in cardiovascular physiology, bacterial pathophysiology and inflammatory diseases. In this review we have discussed adenosine and its congeners as potential promising agents in the treatment of Huntington's disease, post-traumatic stress disorder, erectile dysfunction, viral infections (SARS-CoV) and anxiety.
Rohit Batra, Vinay Jain, Pankaj Sharma100 μl1 mg200ul25 mg100 mg100ul0.5 mg50 mg 100ul 1 G2.5 mg
#34680083 2021/10/02 To Up
The Histamine H Receptor Participates in the Anti-Neuropathic Effect of the Adenosine A Receptor Agonist IB-MECA: Role of CD4 T Cells.A adenosine receptor (AAR) agonists have emerged as potent relievers of neuropathic pain by a T cell-mediated production of IL-10. The H histamine receptor (HR), also implicated in pain modulation, is expressed on T cells playing a preeminent role in its activation and release of IL-10. To improve the therapeutic opportunities, this study aimed to verify the hypothesis of a possible cross-talk between AAR and HR in the resolution of neuropathic pain. In the mouse model of Chronic Constriction Injury (CCI), the acute intraperitoneal co-administration of the AAR agonist IB-MECA (0.5 mg/kg) and the HR agonist VUF 8430 (10 mg/kg), were additive in counteracting mechano-allodynia increasing IL-10 plasma levels. In HR mice, IB-MECA activity was reduced, lower pain relief and lower modulation of plasma IL-1Î², TNF-Î±, IL-6 and IL-10 were shown. The complete anti-allodynia effect of IB-MECA in HR mice was restored after intravenous administration of CD4 T cells obtained from naÃ¯ve wild type mice. In conclusion, a role of the histaminergic system in the mechanism of AAR-mediated neuropathic pain relief was suggested highlighting the driving force evoked by CD4 T cells throughout IL-10 up-regulation.
Laura Micheli, Mariaconcetta Durante, Elena Lucarini, Silvia Sgambellone, Laura Lucarini, Lorenzo Di Cesare Mannelli, Carla Ghelardini, Emanuela Masini